AZD5069 + durvalumab

AZD5069 + durvalumab is a combination therapy comprising AZD5069, an oral small molecule inhibitor of CXC chemokine receptor 2 (CXCR2), and durvalumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1). AZD5069 acts by blocking CXCR2-mediated neutrophil recruitment and reprogramming neutrophil phenotypes in the tumor microenvironment. Durvalumab inhibits the interaction between PD-L1 and its receptors, enhancing T cell-mediated antitumor immunity. This combination is under investigation for use in advanced malignancies, primarily hepatocellular carcinoma and head and neck squamous cell carcinoma, aiming to synergize immunomodulation and targeted therapeutic effects[1][3][5]. It is being evaluated in phase I/II clinical trials for antitumor efficacy, safety, and recommended dosing[1][3][5].

Other names

CXCR2 inhibitor + anti-PD-L1 antibodyAZD5069 in combination with durvalumabAZD-5069 in combination with durvalumabAZD 5069 in combination with durvalumab